Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.73, $0.08 better than the analyst estimate of $0.65. Revenue for the quarter came in at $192.4 million versus the consensus estimate of $191.05 million.

GUIDANCE:

Pacira Pharma sees FY2026 revenue of $735-760 million, versus the consensus of $767.8 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.